81 related articles for article (PubMed ID: 7616451)
1. Pharmacokinetics and pharmacodynamics of recombinant human interleukin-12 in male rhesus monkeys.
Nadeau RR; Ostrowski C; Ni-Wu G; Liberato DJ
J Pharmacol Exp Ther; 1995 Jul; 274(1):78-83. PubMed ID: 7616451
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys.
Li R; Deng F; Fu Y; Zhang Y; Wan H; Zhou D; Gu J; Xu J
Pharmacology; 2010; 85(6):319-27. PubMed ID: 20516733
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
5. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.
Zeuzem S; Hopf U; Carreno V; Diago M; Shiffman M; Grüne S; Dudley FJ; Rakhit A; Rittweger K; Yap SH; Koff RS; Thomas HC
Hepatology; 1999 Apr; 29(4):1280-7. PubMed ID: 10094976
[TBL] [Abstract][Full Text] [Related]
9. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).
Sarmiento UM; Riley JH; Knaack PA; Lipman JM; Becker JM; Gately MK; Chizzonite R; Anderson TD
Lab Invest; 1994 Dec; 71(6):862-73. PubMed ID: 7807968
[TBL] [Abstract][Full Text] [Related]
10. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.
Mager DE; Neuteboom B; Efthymiopoulos C; Munafo A; Jusko WJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):262-70. PubMed ID: 12660309
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
12. TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment.
Teuber G; Rossol S; Lee JH; Dietrich CF; Zeuzem S
Z Gastroenterol; 2002 Jul; 40(7):487-95. PubMed ID: 12122596
[TBL] [Abstract][Full Text] [Related]
13. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.
Van Herpen CM; Huijbens R; Looman M; De Vries J; Marres H; Van De Ven J; Hermsen R; Adema GJ; De Mulder PH
Clin Cancer Res; 2003 Aug; 9(8):2950-6. PubMed ID: 12912941
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
17. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys.
Nadeau RW; Satoh H; Scheide S; Crowl R; Conroy R; Garland WA; Liberato DJ
Drug Metab Dispos; 1995 Sep; 23(9):904-9. PubMed ID: 8565779
[TBL] [Abstract][Full Text] [Related]
18. Is interferon gamma suppression after cardiac surgery caused by a decreased interleukin-12 synthesis?
Franke A; Lante W; Kurig E; Zöller LG; Weinhold C; Markewitz A
Ann Thorac Surg; 2006 Jul; 82(1):103-9. PubMed ID: 16798198
[TBL] [Abstract][Full Text] [Related]
19. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection.
Lee N; Wong CK; Chan PK; Lun SW; Lui G; Wong B; Hui DS; Lam CW; Cockram CS; Choi KW; Yeung AC; Tang JW; Sung JJ
Clin Infect Dis; 2007 Sep; 45(6):723-31. PubMed ID: 17712756
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of recombinant human follicle stimulating hormone after intravenous, intramuscular, and subcutaneous administration in monkeys, and comparison with intravenous administration of urinary follicle stimulating hormone.
Porchet HC; Le Cotonnec JY; Canali S; Zanolo G
Drug Metab Dispos; 1993; 21(1):144-50. PubMed ID: 8095209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]